R
Ralph B. D'Agostino
Researcher at Wake Forest University
Publications - 1336
Citations - 250792
Ralph B. D'Agostino is an academic researcher from Wake Forest University. The author has contributed to research in topics: Framingham Heart Study & Framingham Risk Score. The author has an hindex of 226, co-authored 1287 publications receiving 229636 citations. Previous affiliations of Ralph B. D'Agostino include VA Boston Healthcare System & University of Illinois at Urbana–Champaign.
Papers
More filters
Journal ArticleDOI
Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-Rationale, design, and baseline characteristics
Jennifer B. Green,Adrian F. Hernandez,Ralph B. D'Agostino,Christopher B. Granger,Salim Janmohamed,Nigel P. Jones,Lawrence A. Leiter,Drusilla Noronha,Rachael Russell,Kristina N. Sigmon,Stefano Del Prato,John J.V. McMurray +11 more
TL;DR: Harmony Outcomes will assess the CV safety of albiglutide in patients with T2DM and CV disease and provide information critical to the authors' understanding of this heterogenous class of glucose‐lowering agents.
Journal ArticleDOI
Fracture Risk Assessment in Long-term Care (FRAiL): Development and Validation of a Prediction Model.
Sarah D. Berry,Andrew R. Zullo,Yoojin Lee,Vincent Mor,Kevin W. McConeghy,Geetanjoli Banerjee,Ralph B. D'Agostino,Lori A. Daiello,David Dosa,Douglas P. Kiel +9 more
TL;DR: The FRAiL model was developed specifically to identify NH residents at greatest risk for hip fracture, and it identifies a different pattern of risk factors compared with community models, which could be used to screen NH residents for fracture risk and to target intervention strategies.
Journal ArticleDOI
An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial.
John M. Flack,Deepak L. Bhatt,David E. Kandzari,David L. Brown,Sandeep Brar,James W. Choi,Ralph B. D'Agostino,Cara East,Barry T. Katzen,Lilian Lee,Martin B. Leon,Laura Mauri,William W. O'Neill,Suzanne Oparil,Krishna J. Rocha-Singh,Raymond R. Townsend,George L. Bakris +16 more
TL;DR: There appears to be effect modification by race with individual-level patient characteristics in both treatment arms that affect the observed pattern of SBP responses.
Journal ArticleDOI
One-year outcomes of out-of-hospital administration of intravenous glucose, insulin, and potassium (GIK) in patients with suspected acute coronary syndromes (from the IMMEDIATE [Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care] Trial).
Harry P. Selker,James E. Udelson,Joseph M. Massaro,Robin Ruthazer,Ralph B. D'Agostino,John L. Griffith,Patricia R. Sheehan,Patrice Desvigne-Nickens,Yves Rosenberg,Xin Tian,Ellen M Vickery,James M Atkins,Tom P. Aufderheide,Assaad Sayah,Ronald G. Pirrallo,Michael Levy,Michael E. Richards,Darren Braude,Delanor D. Doyle,Ralph J. Frascone,Donald J. Kosiak,James M. Leaming,Carin M. Van Gelder,Gert Paul Walter,Marvin A. Wayne,Robert Woolard,Joni R. Beshansky +26 more
TL;DR: The Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency care Trial of very early intravenous glucose-insulin-potassium for acute coronary syndromes (ACS) in out-of-hospital emergency medical service (EMS) settings showed 80% reduction in infarct size at 30 days, suggesting potential longer-term benefits.
Journal ArticleDOI
SOSTDC1 differentially modulates Smad and beta-catenin activation and is down-regulated in breast cancer
Kathryn A. Clausen,Kimberly R. Blish,Charles E. Birse,Matthew Triplette,Timothy E. Kute,Gregory B. Russell,Ralph B. D'Agostino,Lance D. Miller,Frank M. Torti,Suzy V. Torti +9 more
TL;DR: It is found that SOSTDC1 is expressed in normal breast tissue and this expression is reduced in breast cancer, identifying SOST DC1 as a clinically important extracellular regulator of multiple signaling pathways in Breast cancer.